NCT04141072 is a clinical trial of Shrunken Pore Syndrome in Kidney Diseases, sponsored by Henrik Bjursten.

Who is sponsoring NCT04141072?

NCT04141072 is sponsored by Henrik Bjursten.

What drugs are being tested in NCT04141072?

Interventions in NCT04141072: Shrunken Pore Syndrome.

What condition does NCT04141072 study?

NCT04141072 studies Kidney Diseases.

Is NCT04141072 still recruiting?

NCT04141072 is currently completed. Last updated 21 September 2021.

Last reviewed 2021-09-21 · How we verify

NCT04141072

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Shrunken Pore Syndrome: a Retrospective, Single Center, Cohort Study

Completed Last updated 21 September 2021

What this trial tests

trial testing Shrunken Pore Syndrome in Kidney Diseases in 4,719 participants. Completed in 10 January 2019.

Timeline

1 January 2010

Primary endpoint
30 December 2015

10 January 2019

Quick facts

Lead sponsor	Henrik Bjursten
Status	Completed
Study type	OBSERVATIONAL
Enrollment	4,719
Start date	1 January 2010
Primary completion	30 December 2015
Estimated completion	10 January 2019
Sites	1 location across Sweden

Drugs / interventions tested

Shrunken Pore Syndrome

Conditions studied

Kidney Diseases — all drugs for Kidney Diseases →

Sponsor

Henrik Bjursten

Who can join

18 and older, any sex, with Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To study the impact a difference in renal clearance of small and large molecules has on long-term survival.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Reduced renal elimination of larger molecules is a strong predictor for mortality.
Herou E, Grubb A, Dardashti A, Nozohoor S, et al · · 2022 · cited 5× · PMID 36266435 · DOI 10.1038/s41598-022-22433-4

Verify or expand the search:

Other recruiting trials for Kidney Diseases

Currently open trials in the same condition.

NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
NCT07217535 — Rutgers University Study of the Genetics of Kidney Disease · recruiting
NCT06858319 — Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. · Phase 3 · recruiting
NCT06798909 — Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients · Phase 3 · recruiting
NCT06759077 — Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04141072 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Henrik Bjursten
Last refreshed: 21 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04141072.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing